Shareholding members of the company’s board of directors and management have entered into agreement not to sell their shares and/or other securities in the company in any way, also known as lock-up agreements, during the period from and including January 1, 2026, until and including June 30, 2026. The lock-up prevents transfer or disposal of shares and/or other securities in the company, with customary exceptions. 

“SynAct Pharma is entering a pivotal phase, with significant clinical progress in our Phase 2B ADVANCE trial in Rheumatoid Arthritis and in our parallel development track in viral infections. The Board’s decision to enter lock-up agreements signals our firm belief in the company’s potential and readiness for the next stages of growth, including the opportunities we see ahead for strategic partnerships,” said Anders Kronborg, Chairman of the Board of Directors, SynAct Pharma.

“We are close to finalizing recruitment in the Phase 2b ADVANCE study and we are eager to report on the progress and subsequently the topline results. To ensure full transparency we have decided that our management group and our Board will not be able to make transactions until we report the topline results,” said Jeppe Øvlesen, Chief Executive Officer.

“This decision demonstrates our unwavering commitment to SynAct Pharma’s strategy and to our shareholders. With important milestones approaching, including finalization and topline results from our Phase 2B ADVANCE study and the Phase 2a in dengue virus, this lock-up shows that management believes strongly in the company’s future and stands fully behind its trajectory,” said Jeppe Øvlesen, CEO.

The following members of the board of directors and the management with current shareholding have signed lock-up agreements:

• Anders Kronborg, Chairman of the Board
• Sten Sörensen, Board Member
• Sten Scheibye, Board Member
• Jeppe Ragnar Andersen, Board Member
• Jeppe Øvlesen, CEO
• Thomas Jonassen, MD, CSO
• Mads Liebach Bjerregaard, CBO
• Thomas Boesen, PhD, COO